Exhibit 10.2
  
SEVENTH AMENDMENT

This Seventh Amendment, effective as of the last date of signature hereto is
made to the January 13, 2006 Research/Manufacturing Agreement between Schering
Corporation, acting through its Schering-Plough Research Institute division,
having a business address at 2000 Galloping Hill Road, Kenilworth, New Jersey
07033 (“SPRI”) and Albany Molecular Research, Inc., having a business address at
26 Corporate Circle, Albany, New York 12203-5154 (together with its subsidiaries
and affiliates hereinafter collectively referred to as “AMRI”) as amended on
June 15, 2006, January 2, 2007, January 3, 2008, November 19, 2008, March 9,
2009, and March 27, 2009 (collectively, as amend  the “Agreement”).

WITNESSETH:

WHEREAS, SPRI and AMRI desire to extend the term of the Agreement, amend the
termination section, amend the FTE rate in the Agreement, and amend to add
affiliate language.

NOW, THEREFORE, SPRI and AMRI agree to amend the Agreement as follows:

 
1.
Delete the text of Section E.1.of the Agreement in its entirety and replace it
with the following:

“This Agreement shall commence on the date first set forth above and shall
terminate on March 31, 2015, unless earlier terminated by either party (the
“Term”).  The Term of this Agreement may be extended by mutual written agreement
of the parties.

 
2.
Delete the text of Section E.3.d. of the Agreement in its entirety and replace
it with the following:

“[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] may terminate this Agreement or any
Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] upon written notice to
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] under the [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/]:
 
i. [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

 
Total Number of
[/*[CONFIDENTIAL
TREATMENT
REQUESTED]*/] this
Agreement or any Project
 
Termination Notice
Number of Days
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]s
 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]sdays
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] days

 
1

--------------------------------------------------------------------------------

 
For example, if [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] decides to terminate a
total of [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from any Project or this
Agreement, [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] will give [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] days prior written to
 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] for the first [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] and [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] days prior
written notice to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] for the
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/].

[CONFIDENTIAL TREATMENT REQUESTED BY AMRI – 09]

 
3.
In Section F.2.a. of the Agreement the FTE rate table is deleted in its entirety
and replaced with the following:

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Based FTEs
 
Total Number of
FTEs
 
[/*[CONFIDENTIAL
TREATMENT
REQUESTED]*/]
Price Per FTE (in US
Dollars)
 
Estimated [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] Expenses per
[/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] per FTE (in US Dollars)
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

 
2

--------------------------------------------------------------------------------

 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Based FTEs
  
Total Number of
FTEs
 
[/*[CONFIDENTIAL
TREATMENT
REQUESTED]*/]
Price Per FTE (in US
Dollars)
 
Estimated [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] Expenses
per [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] per FTE (in US Dollars)
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]s

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Based FTEs
 
Total Number of
FTEs
 
[/*[CONFIDENTIAL
TREATMENT
REQUESTED]*/]
Price Per FTE (in
U.S. Dollars)
 
Estimated [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] Expenses per
[/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] per FTE (in US Dollars)
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
 
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

* [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] based FTEs rates do not include
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/].  AMRI shall include the appropriate
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] amount to all invoices for
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] FTEs.

[CONFIDENTIAL TREATMENT REQUESTED BY AMRI – 10]

4.      Add Section L as follows:

L.  Affiliate Language:

1.      For purposes of this Agreement, the term “Affiliate” means (1) any
corporation or business entity of which fifty percent (50%) or more of the
voting stock or voting equity interests  are owned directly or indirectly by a
PARTY; or (2) any corporation or business entity which directly or indirectly
owns fifty percent (50%) or more of the voting stock or voting equity interests
of a party; or (3) any corporation or business entity directly or indirectly
controlling or under control of a corporation or business entity as described in
(1) or (2).  An Affiliate shall be permitted to utilize the AMRI Services for
any Project, under this Agreement and shall be bound by the terms and conditions
this Agreement as if a party hereto.
 
3

--------------------------------------------------------------------------------

 
 
5.
Capitalized terms used and not otherwise defined herein shall have the meaning
given to them in the Agreement. Except for the foregoing, all of the terms and
conditions of the Agreement are hereby ratified and confirmed shall remain in
full force and effect.  This Seventh Amendment may not be modified or amended
unless in writing and signed by the parties hereto.

IN WITNESS WHEREOF, the parties have caused this Seventh Amendment to be
executed by their duly authorized representatives.

ALBANY MOLECULAR RESEARCH, INC.
 
SCHERING CORPORATION,
   
acting through its Schering-Plough
   
Research Institute division
         
By:
Michael P. Williams
 
By:
Willie A. Deese
 
authorized representative
   
authorized representative
Name:
Michael P. Williams
 
Name:
Willie A. Deese
         
Title:
Vice President, Legal Affairs
 
Title:
EVP & President
         
Date:
July 14, 2010
 
Date:
July 8, 2010

 
4

--------------------------------------------------------------------------------